CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer
Sam Z. Thalji(Medical College of Wisconsin), Susan Tsai(The Ohio State University Wexner Medical Center), Parag Tolat(Medical College of Wisconsin), Bradley A. Erickson(Medical College of Wisconsin), Callisia N. Clarke(Medical College of Wisconsin), Kathleen K. Christians(Medical College of Wisconsin), Zachary L. Smith(Washington University in St. Louis), Mohammed Aldakkak(Medical College of Wisconsin), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), William A. Hall(Medical College of Wisconsin), Ben George(Medical College of Wisconsin), Mandana Kamgar(Medical College of Wisconsin)
Cited by 14
Related Papers
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
|Radiotherapy and Oncology|2006|1.6k
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer
|International Journal of Radiation Oncology*Biology*Physics|2010|458
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models
|BMC Cancer|2018|391
Population-Based Study of Islet Cell Carcinoma
|Annals of Surgical Oncology|2007|338